Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

Meulendijks Didier; de Groot Jan Willem B; Los Maartje; Boers James E; Beerepoot Laurens V; Polee Marco B; Beeker Aart; Portielje Johanna E A; Goey Swan H; de Jong Robert S; Vanhoutvin Steven A L W; Kuiper Maria; Sikorska Karolina; Pluim Dick; Beijnen Jos H; Schellens Jan H M; Grootscholten Cecile; Tesselaar Margot E T; Cats Annemieke

SCI

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study

摘要

关键词